Eliquis (apixaban) is a prescription anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is one of the most widely prescribed anticoagulants, and is considered to be an effective and safe treatment option for many patients. However, there are potential risks associated with Eliquis, particularly in the elderly population. This article will discuss the potential risks of Eliquis in the elderly, including side effects, potential interactions with other medications, and the importance of monitoring for adverse reactions.
Eliquis is a direct factor Xa inhibitor, which works by blocking the action of factor Xa, a protein involved in the clotting process. This helps to prevent the formation of blood clots, which can cause serious health problems such as stroke, heart attack, and pulmonary embolism. Eliquis is generally well-tolerated, but it is important to be aware of the potential risks associated with taking this medication.
The elderly population is particularly vulnerable to the side effects of Eliquis. Common side effects of Eliquis include nausea, headache, dizziness, and fatigue. Elderly patients may also be more likely to experience bleeding, including bleeding from the nose, gums, or rectum, as well as bruising more easily. In some cases, Eliquis can also cause anemia, which can lead to fatigue and shortness of breath.
Eliquis can interact with other medications, including non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and other anticoagulants. It is important to discuss all medications that a patient is taking with their doctor, as some medications may increase the risk of bleeding or other side effects when taken with Eliquis.
It is important for elderly patients taking Eliquis to be monitored closely for any adverse reactions, such as bleeding or bruising. Patients should also be aware of the signs and symptoms of anemia, such as fatigue and shortness of breath. Regular blood tests should be done to monitor for any changes in the blood.
Eliquis is a widely prescribed anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. While Eliquis is generally well-tolerated, there are potential risks associated with taking this medication, particularly in the elderly population. It is important to be aware of the potential side effects of Eliquis, as well as any potential interactions with other medications. Regular monitoring for adverse reactions is also important, as this can help to detect any problems early and reduce the risk of serious complications.
1.
Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.
2.
New policy review highlights the importance of health-related quality of life in advanced cancer
3.
In myelofibrosis, combinations of rufolitinib reduce spleen volume.
4.
Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities
5.
More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.
1.
The Benefits of Understanding Haptoglobin High: What You Need to Know
2.
Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment
3.
Unraveling the Complexities of Embryonal Carcinoma: A New Hope for Treatment
4.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
5.
Colorectal Cancer Uncovered: CME, Case Studies, and Clinical Strategies
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
5.
Blood Clotting Disorders Explained
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation